MedPath

Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: Vehicle
Registration Number
NCT01873677
Lead Sponsor
Maruho North America Inc.
Brief Summary

This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
537
Inclusion Criteria
  • Who are able and willing to give signed informed consent
  • Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator.
  • Who have up to 20% of body surface area (BSA) afflicted with plaques
  • Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study.
Exclusion Criteria
  • Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
  • Who are pregnant or lactating.
  • Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
  • Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
  • Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
  • Whose serum calcium levels exceed the upper limit of reference range
  • Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of randomization.
  • Who have been treated with systemic therapy within 30days of randomization.
  • Who have treated with biologics within 5 half-lives of the biologics before the day of randomization
  • Who have been treated with topical therapy within 14days before the day of randomization.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
M518101M518101Proper quantity twice a day
VehicleVehicleProper quantity twice a day
Primary Outcome Measures
NameTimeMethod
Investigator Global Assessment8 weeks after dosing
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (30)

Coastal Clinical Research

🇺🇸

Mobile, Alabama, United States

The Center for Skin Research

🇺🇸

Houston, Texas, United States

Dawes Fretzin Clinical Research Group

🇺🇸

Indianapolis, Indiana, United States

Skin Surgery Medical Group

🇺🇸

San Diego, California, United States

Belleair Research Center

🇺🇸

Pinellas Park, Florida, United States

Olympian Clinical Research

🇺🇸

Tampa, Florida, United States

Derm Dox Center for Dermatology

🇺🇸

Hazelton, Pennsylvania, United States

International Dermatology Research Inc

🇺🇸

Miami, Florida, United States

FXM Research Miramar

🇺🇸

Miramar, Florida, United States

Minnesota Clinical Study Center

🇺🇸

Fridley, Minnesota, United States

Dermatology Associates

🇺🇸

Seattle, Washington, United States

Suzanne Bruce and Associates The Center for Skin Research

🇺🇸

Katy, Texas, United States

Omni Dermatology

🇺🇸

Phoenix, Arizona, United States

University Clinical Trials

🇺🇸

San Diego, California, United States

Visions Clinical Research

🇺🇸

Boynton Beach, Florida, United States

The Savin Center

🇺🇸

New Haven, Connecticut, United States

North Florida Dermatology Associates

🇺🇸

Jacksonville, Florida, United States

Wake Forest University

🇺🇸

Winston Salem, North Carolina, United States

Clinical Partners

🇺🇸

Johnston, Rhode Island, United States

Dermatology Clinical Res.

🇺🇸

San Antonio, Texas, United States

Rhode Island Hospital Dermatology

🇺🇸

Providence, Rhode Island, United States

Center for Clinical Studies

🇺🇸

Webster, Texas, United States

The Indiana Clinical Trials Center

🇺🇸

Plainfield, Indiana, United States

PMG research of Raleigh

🇺🇸

Cary, North Carolina, United States

Renstar Medical Research

🇺🇸

Ocala, Florida, United States

Shondra Smith Dermatology & Advanced Aesthetics

🇺🇸

Lake Charles, Louisiana, United States

Atlantic Dermatology Associates

🇺🇸

Wilmington, North Carolina, United States

Oklahoma University Health Science Center

🇺🇸

Oklahoma City, Oklahoma, United States

Philadelphia Institute of Dermatology

🇺🇸

Fort Washington, Pennsylvania, United States

Radiant Research

🇺🇸

Greer, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath